🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are increasing around the world, with figures suggesting over 82 million new cases each year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, also received approval in the same week. This medication, which is additionally indicated for UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This authorization signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Global Access

As per data published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which combines two antibiotics. The study included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have voiced hope. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea worldwide.